Join our daily newsletter At The Bell to receive exclusive market insights
- PharmAust subsidiary Epichem has announced Colin La Galia as its new CEO
- Colin has over 20 years of experience in a senior role
- At the same time, Dr Martine Keenan will resume her role as Epichem’s Head of Drug Discovery
- Shares are up 4 per cent, trading for 13 cents apiece
PharmAust has announced that Colin La Galia has been appointed the new CEO of its subsidiary Epichem.
Colin has previously worked as the Regional Business Director and Commercial Head of Asia Pacific, China, and Japan for Abbott Rapid Diagnostics.
He has also held senior roles for over 20 years at Alera Inc, Origin Healthcare, Hollywood Fertility Centre, Merck Sharpe & Dohme, and GlaxoSmithKline.
Colin is highly experienced in pharmaceuticals, devices and diagnostics both locally and internationally, and has demonstrated success in international business development.
Executive Chairman Dr Roger Aston is pleased to have someone of Colin’s calibre join the team.
“We are all delighted that Colin has decided to join Epichem. He has an outstanding record in driving performance and adding value, and we are confident that Colin will be able to grow and diversify the Epichem business and take the business to the next level of increased revenues and profitability,” he said.
Simultaneously, Dr Martine Keenan will resume her former role as Epichem’s Head of Drug Discovery and will also join its board.
“Martine’s tenure as Epichem CEO has seen the revenues grow to the highest point in Epichem’s fifteen year history and we are delighted that she will be full time Head of Drug Discovery again and also be available to us on the Epichem Board,” Dr Roger said.
“The changes are a win all around for both Epichem and PharmAust,” he added.
PharmAust shares are up 4 per cent, with each one trading for 13 cents apiece.
